NASDAQ:ITRM - Iterum Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.49 +0.62 (+9.02 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$6.87
Today's Range$6.85 - $7.98
52-Week Range$6.69 - $13.00
Volume35,500 shs
Average Volume46,302 shs
Market Capitalization$115.30 million
P/E RatioN/A
Dividend YieldN/A
Iterum Therapeutics logoIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.12
Current Ratio11.53
Quick Ratio11.53


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales209.12
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares13,960,000
Market Cap$115.30 million

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) issued its earnings results on Tuesday, August, 14th. The company reported ($2.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.78. The firm had revenue of $0.19 million for the quarter. View Iterum Therapeutics' Earnings History.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Iterum Therapeutics.

What price target have analysts set for ITRM?

4 brokers have issued 1 year target prices for Iterum Therapeutics' shares. Their predictions range from $18.00 to $24.00. On average, they expect Iterum Therapeutics' share price to reach $20.75 in the next year. This suggests a possible upside of 177.0% from the stock's current price. View Analyst Price Targets for Iterum Therapeutics.

What is the consensus analysts' recommendation for Iterum Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iterum Therapeutics.

Who are some of Iterum Therapeutics' key competitors?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the folowing people:
  • Mr. Corey N. Fishman, Chief Exec. Officer, Pres and Director (Age 53)
  • Ms. Judith M. Matthews, Chief Financial Officer
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 58)
  • Mr. Benjamin M. Pe, VP of Operations
  • Mr. John J. White, VP of Bus. Devel. & Supply Chain

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

When does Iterum Therapeutics' lock-up period expire?

Iterum Therapeutics' lock-up period expires on Wednesday, November 21st. Iterum Therapeutics had issued 6,150,000 shares in its initial public offering on May 25th. The total size of the offering was $79,950,000 based on an initial share price of $13.00. After the end of Iterum Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Has Iterum Therapeutics been receiving favorable news coverage?

Headlines about ITRM stock have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iterum Therapeutics earned a daily sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Iterum Therapeutics.

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Frazier Management LLC (11.02%), Granahan Investment Management Inc. MA (1.73%), Millennium Management LLC (1.23%), Tiverton Asset Management LLC (1.01%), Neuburgh Advisers LLC (0.44%) and Flinton Capital Management LLC (0.37%). Company insiders that own Iterum Therapeutics stock include Corey N Fishman, Judith M Matthews, Michael W Dunne, Patrick J Heron, Paul R Edick and Sofinnova Venture Partners Ix,. View Institutional Ownership Trends for Iterum Therapeutics.

Which institutional investors are buying Iterum Therapeutics stock?

ITRM stock was purchased by a variety of institutional investors in the last quarter, including Frazier Management LLC, Granahan Investment Management Inc. MA, Millennium Management LLC, Tiverton Asset Management LLC, Neuburgh Advisers LLC, Flinton Capital Management LLC, Tyers Asset Management LLC and Dean Capital Investments Management LLC. Company insiders that have bought Iterum Therapeutics stock in the last two years include Corey N Fishman, Judith M Matthews, Michael W Dunne, Patrick J Heron, Paul R Edick and Sofinnova Venture Partners Ix,. View Insider Buying and Selling for Iterum Therapeutics.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $7.49.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $115.30 million and generates $500,000.00 in revenue each year. Iterum Therapeutics employs 38 workers across the globe.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

MarketBeat Community Rating for Iterum Therapeutics (NASDAQ ITRM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about Iterum Therapeutics and other stocks. Vote "Outperform" if you believe ITRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by Staff

Featured Article: Google Finance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel